The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: A cohort of hospitalized patients

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Blasi, Francesco ^a   Cesana, Giancarlo ^b   Conti, Sara ^b   Chiodini, Virginio ^b   Aliberti, Stefano ^b   Fornari, Carla ^b   Mantovani, Lorenzo Giovanni ^b,c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; ITALY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHENOTYPE; QUALITY OF LIFE; SOCIAL PROBLEM; COMPLICATION; ECONOMICS; HOSPITALIZATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84903388330     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101228     Document Type: Article

References (31)

1. (2007) Global surveillance, prevention and control of chronic respiratory disease. A comprehensive approach. In: Press W, editor. WHO Library Cataloguing. Switzerland: WHO.
2. Mathers CD, Loncar D (2006) Projections of Global Mortality and Burden of Disease from 2002 to 2030. Plos Medicine 3: e442-e461.
3. (2008) World Health Statistics 2008. WHO.
4. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, et al. (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31: 416-469.
5. Mapel DW, Roberts MH (2012) New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses. Pharmacoeconomics 30: 869-885.
6. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, et al. (2010) Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine 363: 1128-1138.
7. Rodriguez-Roisin R (2006) COPD exacerbations - 5: Management. Thorax 61: 535-544.
8. Dal Negro R (2008) Optimizing economic outcomes in the management of COPD. International Journal of COPD 3: 1-10.
9. Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS (2010) The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD 7: 214-228.
10. Dalal AA, Christensen L, Liu F, Riedel AA (2010) Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 5: 341-349.
11. Celli BR, MacNee W, Force AET (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal 23: 942-946.
12. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stephen AS (2012) Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. International Journal of COPD 7: 757-764.
13. Løkke A, Hilberg O, Tønnesen P, Ibsen R, Kjellberg J, et al. (2014). Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010. BMJ Open 6;4(1): e004069.
14. Charlson M, Pompei P, Ales K, MacKenzie CR (1987) A new method for classifying comorbidity in longitudinal studies: development and validation. Journal of Chronic Disease 40: 373-383. (Pubitemid 17055592)
15. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, et al. (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical care 43: 1130-1139. (Pubitemid 41587600)
16. Bang H, Tsiatis AA (2000) Estimating medical costs with censored data. Biometrika 87: 329-343.
17. Johnson AK, Mannino DM (2008) Epidemiology of COPD Exacerbations. Chronic Obstructive Pulmonary Disease Exacerbations. London: Informa Healthcare. 15-26.
18. Seemungal TAR, Hurst JR, Wedzicha JA (2009) Exacerbation rate, health status and mortality in COPD - a review of potential interventions. International Journal of COPD 4: 203-223.
19. Suissa S, Dell'Aniello S, Ernst P (2012) Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 67: 957-963.
20. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, et al. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925-931. (Pubitemid 41598207)
21. Almagro P, Calbo E, Ochoa de Echagüen A, Barreiro B, Quintana S, et al. (2002) Mortality after hospitalization for COPD. Chest 2002: 5.
22. Groenewegen KH, Schols AM, Wouters EF (2003) Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124: 459-467. (Pubitemid 37000120)
23. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, et al. (2002) Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57: 759-764. (Pubitemid 34984972)
24. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA (2010) Increased risk of myocardial infarction and stroke following exacerbation of chronic obstructive pulmonary disease. Chest 137: 1091-1097.
25. Monteagudo M, Rodriguez-Blanco T, Parcet J, Peñalver N, Rubio C, et al. (2011) Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. Archivos de Bronconeumologia 47: 226-233.
26. Bertella E, Zadra A, Vitacca M, on behalf of General Practitioners Distretto 04 ASL 02 Brescia I (2013) COPD management in primary care: is an educational plan for GP's useful? Multidisciplinary Respiratory Medicine 8.
27. Abramson MJ, Schattner RL, Sulaiman ND, Birch KE, Simpson PP, et al. (2010) Do spirometry and regular follow-up improve health outcomes in general practice patients with asthma or COPD? A cluster randomised controlled trial. The Medical Journal of Austarlia 193: 104-109.
28. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, et al. (2011) Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. Journal of Medical Economics 14: 315-323.
29. Simoens S, Decramer M, De Coster S, Celis G, Laekeman G (2007) Clinical and economic analysis of antimicrobial therapy of chronic obstructive pulmonary disease exacerbations. International Journal of Clinical Practice 61: 200-206.
30. Celli BR, Decramer M, Kesten S, Liu D, Mehra S, et al. (2009) Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care 180: 948-955.
31. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, et al. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685-694.